Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-04-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
上会会计师事务所（特殊普通合伙）关于上海宣泰医药科技股份有限公司募集资金存放与使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Verification Report) regarding the company's 2024 fundraising funds deposit and usage situation. It is issued by a certified public accounting firm and includes detailed information about the management, storage, and actual use of the funds raised by the company in 2024. The report references compliance with regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and it provides an auditor's opinion on the accuracy and completeness of the fundraising funds usage report. The document contains detailed financial data and audit conclusions specifically about the fundraising capital management and usage, which aligns with the definition of an Audit Report / Information (AR) rather than a full Annual Report or other categories. It is not a simple announcement or certification but a standalone audit verification report on fundraising funds usage. Therefore, the correct classification is AR with high confidence.
2025-04-29 Chinese
关于会计师事务所2024年度履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm for the year 2024. It details the qualifications, risk capacity, audit records, staffing, audit plans, quality management, and information security management of the accounting firm engaged by the company. It does not contain actual financial statements or results but rather assesses the auditor's performance and compliance with regulations. The document length is 2651 characters, which is relatively short and more consistent with an audit-related report rather than a full annual report or interim report. It is not a certification letter or a simple announcement but a detailed evaluation report on the auditor's performance. This fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and evaluations related to audit firms and their work, excluding full annual reports.
2025-04-29 Chinese
内部审计管理制度（2025年4月）
Governance Information Classification · 95% confidence The document is titled '内部审计管理制度' which translates to 'Internal Audit Management System'. It details the internal audit policies, responsibilities, organizational structure, and procedures of the company. It references laws, regulations, and governance guidelines related to internal audit and control. The document is a comprehensive internal policy or governance document rather than a financial report, earnings release, or announcement. It does not contain financial statements, earnings data, voting results, or capital changes. It is not a report publication announcement or a certification. The content fits best under Governance Information (CGR) as it details the company's internal rules and governance practices related to internal audit.
2025-04-29 Chinese
公司章程（2025年4月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Shanghai Sinotherapeutics Inc. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, capital changes, shareholder meetings, and governance rules. It references relevant laws and regulations such as the Company Law of China, Securities Law, and listing rules of the Shanghai Stock Exchange. The content is a comprehensive governance document outlining the internal rules and structure of the company rather than financial results, audit opinions, or meeting announcements. It is not a report of financial performance or an announcement but a governance charter. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, confirming it is not a brief announcement or a report publication notice.
2025-04-29 Chinese
2024年度非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report titled "专项审计报告" related to non-operating fund occupation and other related party fund transactions for Shanghai Xuantai Pharmaceutical Technology Co., Ltd. for the year 2024. It includes detailed audit opinions, tables summarizing fund occupation and related party transactions, and is issued by a certified accounting firm. The document contains substantive financial data and audit findings specific to a particular aspect of the company's financials, rather than a full annual report or general audit report. This fits the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles excluding full annual reports. The document length (9577 characters) and content confirm it is not merely an announcement or certification but a full audit report on a specific topic.
2025-04-29 Chinese
2024年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度募集资金存放与使用情况的专项报告" which translates to "2024 Annual Special Report on the Deposit and Use of Raised Funds." It details the amount of funds raised, their deposit, usage, management, and related regulatory compliance. It references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and includes detailed financial figures about fundraising and usage for the year 2024. The document is a specialized report focusing on the management and use of capital raised by the company, not a general annual report or earnings release. It is not a simple announcement or certification but a substantive report on capital usage. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (9112 characters) and detailed financial data support this classification with high confidence.
2025-04-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.